Alprazolam and Diazepam in the Treatment of Generalized Anxiety

@article{lie1984AlprazolamAD,
  title={Alprazolam and Diazepam in the Treatment of Generalized Anxiety},
  author={Robert {\'E}lie and Yves Lamontagne},
  journal={Journal of Clinical Psychopharmacology},
  year={1984},
  volume={4},
  pages={125–129}
}
In a 4-week double-blind study comparing alprazolam with diazepam treatments, 48 outpatients suffering from mild to moderate generalized anxiety were evaluated after a 5-day placebo washout, and then after 1, 2, and 4 weeks of treatment. The optimal therapeutic doses without excessive sedation averaged 2 mg for alprazolam and 15.8 mg for diazepam. Results from the Hamilton Anxiety Rating Scale, the Clinical Global Impression Scale, a behavior checklist questionnaire, and a symptomatic patients… 

Mexazolam and Alprazolam in the Treatment of Generalised Anxiety Disorder

Both mexazolam and alprazolam showed a significant anxiolytic effect and were well tolerated in the treatment of GAD, making it an effective pharmacotherapeutic alternative in the Treatment of G AD.

Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.

An exhaustive review of the literature showed that alprazolam is significantly superior to placebo, and is at least equally effective in the relief of symptoms as tricyclic antidepressants (TCAs) such as imipramine.

CNS Drug Reviews

Alprazolam is a benzodiazepine derivative that is currently used in the treatment of generalized anxiety, panic attacks with or without agoraphobia, and depression. Alprazolam has a fast onset of

Clinical uses of benzodiazepines. Focus on: benzodiazepines and anxiety disorders

Benzodiazepines have proven very effective in panic disorder, generalized anxiety and, even if to a lower degree, in social phobia, and role in obsessive compulsive disorder and post traumatic stress disorder is not as strong but these medications may be useful for several patients with those diseases.

History repeats itself: pharmacodynamic trends in the treatment of anxiety disorders.

The following paper details the pharmacodynamic history of treating anxiety and also updates the reader as to the newer GABA-based approaches mentioned above.

Benzodiazepines and anxiety disorders: a review for the practicing physician

BZDs remain a mainstay in the treatment of anxiety, as both monotherapy and adjunctive therapy, and factors to consider prior to prescribing a BZD include the patient's diagnosis, as well as drug characteristics, including the potential for interactions with other drugs, the risk of dependence and withdrawal, and the required frequency of dosing.

The diagnosis and treatment of generalized anxiety disorder.

The treatment of GAD with CBT and drugs is evidence-based and has a good chance of improving the manifestations of the disorder.